Dr. Broedur’s two principal research interests center on nanoparticle drug delivery and cancer predisposition. With respect to nanoparticle drug delivery, Dr. Broedur and his colleagues aim to develop more effective and less toxic therapy for pediatric cancers, especially solid tumors like neuroblastoma. Although agents targeting specific genes, proteins, and pathways are needed, targeted drug delivery could dramatically improve efficacy and decrease toxicity.

Dr. Brodeur also has research projects focused on identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals The ultimate aim of this research is to improve outcome and reduce side effects for patients.

BA, St. Louis University (Chemistry), 1971

MD, Washington University School of Medicine, 1975

Director, Cancer Predisposition Program

Audrey E. Evans Endowed Chair in Pediatric Oncology

Attending Physician

Professor of Pediatrics

American Society of Hematology, 1980-

American Society of Clinical Oncology, 1980-

American Association for the Advancement of Science, 1983-

American Society of Pediatric Hematology-Oncology, 1983-

Society for Pediatric Research, 1985-

American Society for Clinical Investigation, 1990-

John Morgan Society, 1996-

Osler Interurban Clinical Club, 2001-

Association of American Physicians, 2015

Faculty Mentor Award, Children's Hospital of Philadelphia, 2011

ASCO Pediatric Oncology Award, 2013

Lifetime Achievement Award, Advances in Neuroblastoma Research Association, 2014

Cancer Predisposition Program (Video)